

ONCE-WEEKLY  
SOGROYA® GIVES YOU

**313**

INJECTION-FREE  
DAYS PER YEAR



# Leave the once-daily baggage **behind** with Sogroya®

Discover Sogroya®: The **FIRST** and **ONLY** once-weekly growth hormone for the treatment of adult growth hormone deficiency (AGHD)

<sup>a</sup>Represents 52 Sogroya® injections per year.

## What is Sogroya®?

- Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body.
- It is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

## Important Safety Information

### Do not use Sogroya® if:

- you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
- you have cancer or other tumors
- you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
- your healthcare provider tells you that you have certain types of eye problems caused by diabetes
- you are a child with closed bone growth plates
- you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)



All patient images  
are for illustrative  
purposes only.



Please see Important Safety Information throughout.  
Please click [here](#) for Prescribing Information.

Go beyond the everyday



ONCE-WEEKLY  
**SOGROYA®**  
somapacitan-beco  
injection 5mg | 10mg | 15mg

## Sogroya® provides key benefits with 1 injection per week

### Sogroya® delivered a greater decrease in truncal fat % vs placebo

In a study of 300 adults who had never been treated for growth hormone deficiency (GHD), Sogroya® was compared with a placebo and daily growth hormone treatment (somatropin) across 34 weeks.



Adults taking Sogroya®: **-1.06% decrease** in truncal fat, from 39.11% at the start of the study



Adults taking placebo: **+0.47% increase** in truncal fat, from 36.9% at the start of the study

- Although no direct comparisons between Sogroya® and daily growth hormone treatment were performed, those who took the daily growth hormone experienced a -2.23% decrease in truncal fat, from 38.1% at the start of the study

According to the expert opinion from the Growth Hormone Research Society, a once-weekly option may help you keep on track and provide flexibility

GH=growth hormone.

### Important Safety Information

#### Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

- have had heart or stomach surgery, trauma, or serious breathing problems
- have had cancer or any tumor
- have diabetes
- have adrenal gland problems
- are taking replacement therapy with glucocorticoids
- have thyroid gland problems

### Compared with daily GH treatments, with Sogroya® you get

**313** INJECTION-FREE DAYS per year

because you only need to take Sogroya® once a week



Day selected is for illustrative purposes only.

#### What happens if a dose is missed?

- If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for your next dose can be started again on your regularly scheduled dosing day
- If more than 3 days (72 hours) have passed, skip the missed dose and take your next dose on your regularly scheduled dosing day

## Sogroya<sup>®</sup> has a proven safety profile

The most common side effects of Sogroya<sup>®</sup> include:

back pain

joint pain

indigestion

sleep problems

dizziness

swelling of the tonsils (tonsillitis)

vomiting

high blood pressure

increase in the level of an enzyme in your blood called creatine phosphokinase

weight gain

low red blood cells (anemia)

Talk to your doctor for medical advice about these and other possible side effects.

### Important Safety Information

**Before taking Sogroya<sup>®</sup>, tell your healthcare provider about all of your medical conditions, including if you:**

- have liver problems
- are a child with a history of worsening of curvature of the spine (scoliosis)
- are pregnant or plan to become pregnant. It is not known if Sogroya<sup>®</sup> will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed. It is not known if Sogroya<sup>®</sup> passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya<sup>®</sup> while you breastfeed

## The Sogroya<sup>®</sup> pen: designed with you in mind



### PORTABLE

Stable at room temperature (up to 77 °F) for up to 3 days (72 hours)<sup>a</sup>



### READY TO USE

Prefilled, premixed, and preloaded



### EASY TO LEARN TO USE<sup>b</sup>

Based on the FlexPro<sup>®</sup> pen patients have been using for more than 10 years

<sup>a</sup>The pen should be refrigerated (36 °F-46 °F). The pen can be taken in and out of a refrigerator as needed. The pen must be discarded 6 weeks after first use, or if it has been frozen, or in temperatures warmer than 86 °F. Keep Sogroya<sup>®</sup> away from direct heat and light.

<sup>b</sup>In a study, 94 people used the Norditropin<sup>®</sup> FlexPro<sup>®</sup> 30 mg pen to inject into a foam cushion and rated it a 6.7 out of 7 (on a scale of 1 to 7, where 1 means “strongly disagree” and 7 means “strongly agree”) as “easy to learn to use.” The Norditropin<sup>®</sup> FlexPro<sup>®</sup> is similar to the Sogroya<sup>®</sup> pen.

The Sogroya<sup>®</sup> pen is compatible with NovoFine<sup>®</sup> needles—designed to minimize pain.

*Pen is for illustrative purposes only.*

## The pen is provided in 3 dosing strengths. Your doctor will prescribe the dose that is right for you.

5 mg/1.5 mL



Dials in 0.025 mg increments and delivers doses from 0.025 mg to 2 mg

10 mg/1.5 mL



Dials in 0.05 mg increments and delivers doses from 0.05 mg to 4 mg

15 mg/1.5 mL



Dials in 0.1 mg increments and delivers doses from 0.1 mg to 8 mg

Read the Instructions for Use in the Prescribing Information for how to use the Sogroya<sup>®</sup> pen.

## Important Safety Information

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya<sup>®</sup> may affect the way some medicines work, and some medicines may affect how Sogroya<sup>®</sup> works.

## How should I use Sogroya<sup>®</sup>?

- Use Sogroya<sup>®</sup> exactly as your healthcare provider tells you to
- Use Sogroya<sup>®</sup> **1 time each week**
- If you miss a dose of Sogroya<sup>®</sup>, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
- If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
- Sogroya<sup>®</sup> pens are for use by 1 person only
- **Do not share your Sogroya<sup>®</sup> pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them**

# Some questions you may have about taking Sogroya®

## Talk with your doctor about how Sogroya® is taken

### Q: Can I choose the day that I take Sogroya®?

A: When you first start Sogroya®, you'll choose the day to first inject. So, if you first inject on a Wednesday, you'll take the next dose on the following Wednesday. If you forget to take Sogroya® on that day, take it as soon as possible within 3 days (72 hours)—in our example, Thursday, Friday, or Saturday. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day. If you forget to take it within those days, then just skip the missed dose and take your next dose on your regular scheduled dosing day (Wednesday, in our example).

### Q: What can help me remember to take Sogroya® each week?

A: Setting up an ongoing reminder on your phone, computer, or calendar is one of many ways to remember and to get into a habit. Work it into an existing weekly routine.

### Q: Where should I inject my dose?

A: Sogroya® should only be injected under the skin of your stomach area (abdomen), upper arms, upper legs (thighs), or buttocks as instructed by your healthcare provider.

### Q: Should I change the areas of my body where I inject?

A: Change the injection site every week. Always remember to use a new needle for each injection.



## Important Safety Information

### What are the possible side effects of Sogroya®?

#### Sogroya® may cause serious side effects, including:

- high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
- increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. You or your child's healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child's skin
- new or worsening high blood sugar or diabetes. You or your child's blood sugar may need to be monitored during treatment with Sogroya®
- increase in pressure in the skull. If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
- serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating


# NovoCare®— here for you every step of the way

Patient assistance programs  
to fit your needs

## Resources

- Patient Assistance Program (PAP) for eligible patients<sup>a</sup>
- Sogroya® savings card offer
- JumpStart™ program to avoid delay in therapy initiation
- In-person or virtual device training

<sup>a</sup>Eligible uninsured and underinsured patients may receive therapy at no cost until insurance or financial circumstances improve, including patients whose appeals for therapy approval have been denied. Eligibility and restrictions apply.



Visit **NovoCare.com** or  
talk to one of our benefits  
specialists at  
**1-888-NOVO-444**  
**(1-888-668-6444)** to learn more.  
They are available from  
8:00 AM to 8:00 PM ET.

# Leave the once-daily baggage behind with Sogroya®

The **FIRST** and **ONLY** once-weekly treatment for AGHD



AGHD=adult growth hormone disorder.

Ask your doctor about once-weekly Sogroya®—GH treatment that fits your life

## Important Safety Information

### What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

- your or your child's body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child's joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child's healthcare provider if you or your child have any of these signs or symptoms of fluid retention
- decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child's cortisol levels. Tell your or your child's healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
- decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child's thyroid hormone levels
- severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child's healthcare provider if you or your child has any new abdominal pain
- loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child's healthcare provider about rotating the areas where you or your child inject Sogroya®
- worsening of curvature of the spine in children (scoliosis)
- hip and knee pain or a limp in children (slipped capital femoral epiphysis)
- high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
- increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child's healthcare provider will do blood tests to check this

**The most common side effects of Sogroya® in children include:** common cold, headache, fever, pain in extremity, and reaction to injection

**The most common side effects of Sogroya® in adults include:** back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), vomiting, high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call **1-800-FDA-1088**

Please see Important Safety Information throughout. Please click [here](#) for Prescribing Information.



Sogroya®, Norditropin®, and FlexPro® are registered trademarks of Novo Nordisk Health Care AG.

Novo Nordisk and NovoFine® are registered trademarks of Novo Nordisk A/S.

JumpStart™ is a trademark of Novo Nordisk A/S.

© 2023 Novo Nordisk Produced in the U.S.A. US23SOM00111 May 2023

Go beyond the everyday



ONCE-WEEKLY  
**SOGROYA®**  
somapacitan-beco  
injection 5mg | 10mg | 15mg